Trial Outcomes & Findings for Pilot Trial of Statin Use in Burn Patients (NCT NCT00978419)

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

40 participants

Primary outcome timeframe

Days 1, 3, 7, 14

Results posted on

2018-06-01

Participant Flow

Both Principal Investigators left Vanderbilt without completing record. Have been unable to find any records from this study or publication. Total enrollment and completion date are from IRB records.

Participant milestones

Participant milestones
Measure	Rosuvastatin Rosuvastatin Rosuvastatin: Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days	Placebo Placebo Placebo: Placebo administered every day for up to 28 days
Overall Study STARTED	0	0
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Pilot Trial of Statin Use in Burn Patients

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: Days 1, 3, 7, 14

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 90 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 90 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 28 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 90 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 90 days

Outcome measures

Outcome data not reported

Adverse Events

Rosuvastatin

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Placebo

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Burn Unit Director

Vanderbilt University Medical Center

Phone: (615) 322-4590

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place